Speaking at the 25th Wharton India Economic Forum, he said the Indian pharma industry ensured the continuity of supplies

Sputnik V vaccine phase 3: The Data and Safety Monitoring Board (DSMB) had reviewed the safety data from phase 2 trials of the vaccine and stated that there were no safety concerns attached to the jab earlier this week

Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine

Stocks to watch today on January 12:  GAIL, Tata Motors, Dr Reddy, M&M, HUL, Force Motors, Sunteck Realty among others are the top stocks to watch out for in Tuesday's trading session

Initial 30 crore vaccinations (60 crore doses) planned by the Centre would have cost Rs 13,200 crore. However, need for 66 crore doses raises the cost by Rs 1320 crore

There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine

Coronavirus vaccine in India: Adar Poonawalla, CEO of Serum Institute of India that is manufacturing Covishield had said that the company is ready to roll out its vaccine in the coming weeks

Coronavirus vaccine: Russia launched a voluntary vaccination programme with the Russia-made Sputnik V vaccine earlier in December, starting with the most vulnerable groups in Moscow

The vaccine development process by Bharat Biotech, Biological E Ltd and Aurobindo Pharma are currently in various stages, while Dr Reddy's and Hetero have tie ups for manufacturing the vaccine

In India, RDIF has tied up with Dr Reddy's Laboratories for trials and regulatory approvals. Dr Reddy's recently began phase-2 and 3 clinical trials after getting requisite clearance

Alka Sharma, an adviser with the Department of Biotechnology said more than 100 participants from Afghanistan, Bhutan, Maldives, Mauritius, Nepal, Sri Lanka took part in this training programme

Calculation was based on the analysis of data of volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol

Both Pfizer and Moderna have admitted that taking their vaccines could result in side-effects similar to mild Covid symptoms such as muscle pain, chills and a headache

Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation

Coronavirus vaccine update: The ministry also said that India has eight coronavirus vaccine candidates in the making. Out of the eight, two have applied for emergency use authorisation

As per the Indian Council of Medical Research (ICMR), Serum Institute has manufactured four crore doses of the vaccine under the at-risk manufacturing and stockpiling licence obtained from the DCGI

COVID-19 vaccine trial updates: AIIMS director Dr Randeep Guleria has pinned his hopes on the five coronavirus vaccine candidates which are in varying stages of trials across India

However, VK Paul, who heads the National Task Force on COVID-19, had said in November that the arrival of the Pfizer vaccine in India might take months.

The decision comes as Russia recorded 589 new deaths on a day; Russian Deputy Prime Minister Tatiana Golikova that large-scale vaccinations on voluntary basis will began across the country soon

Pfizer and BioNTech vaccine: The UK has already ordered 40 million doses of the Pfizer vaccine to vaccinate its 20 million population, of which around 10 million doses will be available soon